NKTR Nektar Therapeutics
Health Care, filed as NEKTAR THERAPEUTICS (COM NEW), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab
In 2026 Q3 Nathan Fischel added to Nektar Therapeutics.
Who owns this now
Largest portfolio weights among holders, up to 4.2% (Nathan Fischel, DAFNA Capital Management). Not free-float ownership.
Who owns NKTR
Sorted by value, long equity only, as of 2026 Q3.
| History | |||||
|---|---|---|---|---|---|
| Nathan Fischel, DAFNA Capital Management | Add +1.6% | 323,380 | $20M | History |
Insider trades
Open-market buys and sales by NKTR's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- $2.1M sold by 2 insiders under 10b5-1 plans
-
Jonathan Zalevsky Chief R&D OfficerPlanned sale$398K 5,681 shares at $70.00 37% of stakeTraded Jun 30 Filed Jul 2
-
Howard W. Robin CEOPlanned sale$1.2M 20,000 shares at $60.75 27% of stakeTraded Jun 16–17 Filed Jun 18
-
Jonathan Zalevsky Chief R&D OfficerPlanned sale$336K 5,538 shares at $60.71 26% of stakeTraded Jun 15 Filed Jun 17
-
Jonathan Zalevsky Chief R&D OfficerPlanned sale$138K 3,867 shares at $35.67 15% of stakeTraded Jan 20 Filed Jan 22
Also filed in the last 12 months, not counted as buying or selling: 11 sales to cover taxes and 7 stock grants.
SEC filings
Recent issuer filings from EDGAR, 24 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 10-Q | Filing Doc | ||
| 8-K | 7.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 1.01,5.02,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 8-K | 1.01,8.01,9.01 | Filing Doc |
No filings match this filter.
Financials
US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.
Income statement
Balance sheet
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total current assets | $330.7M | $261.29M | $266.27M |
| Total non-current assets * | $67.33M | $42.56M | $14.14M |
| Total assets | $398.03M | $303.85M | $280.41M |
| Total current liabilities | $51.27M | $61.4M | $53.54M |
| Total non-current liabilities * | $215.78M | $181.71M | $137.04M |
| Total equity | $130.99M | $60.74M | $89.83M |
Ownership over time
13Fs that reported it each quarter. Click a bar for that quarter’s holders.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon